GlassScriptPhysician profile
Bella Shalamova
NPI 1861850513
$10,066.64
in general payments reported to CMS, 2019-2025
49 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,361 · 2022: $1,875 · 2023: $2,053 · 2024: $2,695 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,678 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,677.70 |
| Education | $153.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,745.43 | 2021-2025 | |
| Harmony Biosciences LLC | $1,488.10 | 2022-2025 | Wakix |
| Pfizer INC. | $493.89 | 2023-2025 | |
| Argenx US, INC. | $477.04 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $443.75 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $416.20 | 2022-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $394.32 | 2021-2025 | Vumerity, Plegridy, Leqembi |
| Novartis Pharmaceuticals Corporation | $333.72 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $302.11 | 2022-2023 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $297.95 | 2022 | |
| Axsome Therapeutics, INC. | $206.19 | 2025 | Symbravo, Auvelity |
| Sk Life Science, INC. | $188.68 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $171.97 | 2022 | |
| Zoll Respicardia, INC. | $167.58 | 2024-2025 | Remede System |
| Ucb, INC. | $161.61 | 2021-2025 | Fintepla |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $158.74 | 2022-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $153.62 | 2021-2025 | Mavenclad |
| Amgen INC. | $145.16 | 2023-2025 | Uplizna, Aimovig |
| Sumitomo Pharma America, INC. | $144.79 | 2023-2024 | Aptiom |
| Supernus Pharmaceuticals, INC. | $143.11 | 2021-2025 | Qelbree |
| Mallinckrodt Hospital Products INC. | $133.41 | 2021-2025 | Acthar |
| Genentech USA, INC. | $129.55 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $118.54 | 2023-2024 | Nuedexta |
| Lilly USA, LLC | $111.22 | 2021-2025 | Kisunla |
| Biohaven Pharmaceuticals, INC. | $97.78 | 2021 | |
| Arbor Pharmaceuticals, INC. | $96.43 | 2021-2022 | |
| Eisai INC. | $90.76 | 2022-2025 | |
| Medtronic, INC. | $87.26 | 2024-2025 | Percept PC Brainsense |
| Lundbeck LLC | $87.07 | 2023-2024 | Vyepti |
| Azurity Pharmaceuticals, INC. | $82.18 | 2024-2025 | Horizant |
| Ipsen Biopharmaceuticals, INC | $80.91 | 2024-2025 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $78.24 | 2024 | Hyqvia |
| Jazz Pharmaceuticals INC. | $68.81 | 2023-2025 | |
| Horizon Therapeutics Plc | $67.86 | 2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $66.73 | 2022 | |
| Corium, LLC | $65.96 | 2022 | |
| Scilex Pharmaceuticals INC. | $60.93 | 2024 | |
| Vanda Pharmaceuticals INC. | $58.84 | 2024 | Ponvory |
| Impel Pharmaceuticals INC. | $48.52 | 2023 | Trudhesa |
| Acorda Therapeutics, INC | $47.26 | 2024 | Ampyra |
| Avanir Pharmaceuticals, INC. | $46.60 | 2022 | |
| Almatica Pharma LLC | $41.47 | 2022-2023 | Gralise |
| Merz Pharmaceuticals, LLC | $27.92 | 2025 | Xeomin, Inbrija |
| Neurelis, INC. | $25.45 | 2023 | Valtoco |
| Kyowa Kirin, INC. | $23.19 | 2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $22.50 | 2021 | |
| Octapharma USA, INC. | $22.19 | 2025 | Panzyga |
| Livanova USA, INC. | $20.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Shalamova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.